Moreno Franco

Nov 18, 2024 | ccforum.biomedcentral.com | Moreno Franco

ReferencesZhong L, Huang L. Inhalation NO in the HFNC group may result in a meaningless extension of survival time. Crit Care Lond Engl. 2024;28(1):370. Article  Google Scholar  Isha S, Balasubramanian P, Hanson AJ, Jonna S, Raavi L, Khadka S, et al. Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study. Crit Care. 2024;28(1):344. Article  PubMed  PubMed Central  Google Scholar  Austin PC.

Oct 24, 2024 | ccforum.biomedcentral.com | Sinclair De Frías |Syed Anjum |Ricardo Diaz |Ricardo Díaz |Moreno Franco

During the study period, 8098 patients were screened. Of these patients, 346 received inhaled nitric oxide (iNO). We subdivided our patients into two cohorts: those who were spontaneously breathing with (n = 153) or without iNO (n = 1726) use and those who were intubated then were started (n = 193) or were not started (n = 695) on iNO. This cohort included 1879 spontaneously breathing patients. Among these, 153 received iNO while on HFNC/ NIV, and 1726 did not.